Gary L. Olson

1.9k total citations
37 papers, 1.2k citations indexed

About

Gary L. Olson is a scholar working on Molecular Biology, Organic Chemistry and Immunology. According to data from OpenAlex, Gary L. Olson has authored 37 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 12 papers in Organic Chemistry and 7 papers in Immunology. Recurrent topics in Gary L. Olson's work include Chemical Synthesis and Analysis (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (5 papers). Gary L. Olson is often cited by papers focused on Chemical Synthesis and Analysis (9 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and T-cell and B-cell Immunology (5 papers). Gary L. Olson collaborates with scholars based in United States, Switzerland and Canada. Gary L. Olson's co-authors include David Bolin, Charles M. Cook, G. Saucy, Paul Gillespie, David C. Fry, Marcos Hatada, Bradford Graves, Mary Pat Bonner, Michael Bös and David E. Hill and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Gary L. Olson

37 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary L. Olson United States 19 774 469 128 116 114 37 1.2k
Shin‐ichi Tsukamoto Japan 22 765 1.0× 652 1.4× 119 0.9× 123 1.1× 147 1.3× 71 1.6k
Elizabeth A. Lunney United States 25 1.0k 1.4× 583 1.2× 158 1.2× 118 1.0× 217 1.9× 59 1.8k
John W. Ellingboe United States 25 893 1.2× 906 1.9× 81 0.6× 113 1.0× 122 1.1× 54 1.8k
Jefferson Tilley United States 20 683 0.9× 563 1.2× 98 0.8× 65 0.6× 160 1.4× 64 1.4k
John J. Piwinski United States 21 538 0.7× 565 1.2× 113 0.9× 122 1.1× 90 0.8× 49 1.1k
Steven E. Hall United States 20 952 1.2× 574 1.2× 50 0.4× 139 1.2× 126 1.1× 40 1.5k
John H. Hutchinson United States 26 882 1.1× 654 1.4× 214 1.7× 279 2.4× 147 1.3× 90 1.9k
William Seibel United States 22 943 1.2× 438 0.9× 93 0.7× 97 0.8× 176 1.5× 66 1.6k
Derek R. Buckle United Kingdom 23 999 1.3× 1.1k 2.4× 84 0.7× 249 2.1× 135 1.2× 67 2.0k
Robert S. Wilhelm United States 19 580 0.7× 970 2.1× 99 0.8× 190 1.6× 204 1.8× 25 1.7k

Countries citing papers authored by Gary L. Olson

Since Specialization
Citations

This map shows the geographic impact of Gary L. Olson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary L. Olson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary L. Olson more than expected).

Fields of papers citing papers by Gary L. Olson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary L. Olson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary L. Olson. The network helps show where Gary L. Olson may publish in the future.

Co-authorship network of co-authors of Gary L. Olson

This figure shows the co-authorship network connecting the top 25 collaborators of Gary L. Olson. A scholar is included among the top collaborators of Gary L. Olson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary L. Olson. Gary L. Olson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Youssef, Emile, et al.. (2024). Targeting the SMURF2-HIF1α axis: a new frontier in cancer therapy. Frontiers in Oncology. 14. 1484515–1484515. 3 indexed citations
2.
Eggenhuizen, Peter J., Gary L. Olson, Christopher R. Self, et al.. (2019). HLA-DR15-specific inhibition attenuates autoreactivity to the Goodpasture antigen. Journal of Autoimmunity. 103. 102276–102276. 5 indexed citations
3.
Wagner, Jessica, C. Leah B. Kline, Marie D. Ralff, et al.. (2017). Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 16(19). 1790–1799. 56 indexed citations
4.
Patel, Hemal H., Lora Hamuro, Byeong Jo Chun, et al.. (2010). Disruption of Protein Kinase A Localization Using a Trans-activator of Transcription (TAT)-conjugated A-kinase-anchoring Peptide Reduces Cardiac Function. Journal of Biological Chemistry. 285(36). 27632–27640. 38 indexed citations
5.
Na, Chan Hyun, et al.. (2007). Inhibition of amyloid β‐peptide production by blockage of β‐secretase cleavage site of amyloid precursor protein. Journal of Neurochemistry. 101(6). 1583–1595. 12 indexed citations
6.
Sarabu, Ramakanth, David Bolin, Robert M. Campbell, et al.. (2002). Oxazole- and Imidazole-Based Ser-Leu Dipeptide Mimetics in Potent Inhibitors of Antigen Presentation by MHC Class II DR Molecules. PubMed. 18(1). 3–7. 2 indexed citations
7.
Falcioni, Fiorenza, Kouichi Ito, Damir Vidović, et al.. (1999). Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules. Nature Biotechnology. 17(6). 562–567. 49 indexed citations
8.
Gillespie, Paul, et al.. (1997). Conformational analysis of dipeptide mimetics. Biopolymers. 43(3). 191–217. 76 indexed citations
9.
Seibert, Karen, Jaime L. Masferrer, Yan Zhang, et al.. (1995). Mediation of Inflammation by Cyclooxygenase-2. Birkhäuser Basel eBooks. 46. 41–50. 121 indexed citations
10.
Olson, Gary L., et al.. (1995). Peptide Mimetics of Thyrotropin-Releasing Hormone Based on a Cyclohexane Framework: Design, Synthesis, and Cognition-Enhancing Properties. Journal of Medicinal Chemistry. 38(15). 2866–2879. 47 indexed citations
11.
Sarabu, Ramakanth, et al.. (1993). Design, synthesis, and three-dimensional structural characterization of a constrained Ω-loop excised from interleukin-1α. Tetrahedron. 49(17). 3629–3640. 8 indexed citations
12.
Olson, Gary L., David Bolin, Mary Pat Bonner, et al.. (1993). Concepts and progress in the development of peptide mimetics. Journal of Medicinal Chemistry. 36(21). 3039–3049. 213 indexed citations
13.
Tilley, Jefferson, Waleed Danho, I. D. KULESHA, et al.. (1992). Structure activity of C‐terminal modified analogs of Ac‐CCK‐7. International journal of peptide & protein research. 39(4). 322–336. 14 indexed citations
14.
Olson, Gary L., Matthew E. Voss, David E. Hill, et al.. (1990). Design and synthesis of a protein .beta.-turn mimetic. Journal of the American Chemical Society. 112(1). 323–333. 65 indexed citations
15.
Georgopapadakou, N H, et al.. (1987). Monocyclic and tricyclic analogs of quinolones: mechanism of action. Antimicrobial Agents and Chemotherapy. 31(4). 614–616. 23 indexed citations
16.
Coffen, David L., et al.. (1984). Syntheses of an antipsychotic pyrrolo[2,3-g]isoquinoline from areca alkaloids. The Journal of Organic Chemistry. 49(26). 5109–5113. 8 indexed citations
17.
Mrozik, Helmut, et al.. (1982). ChemInform Abstract: SUBSTITUTED IMIDAZO(1,2‐A)PYRIDINE‐2‐CARBAMATE ANTHELMINTICS. Chemischer Informationsdienst. 13(22). 5 indexed citations
18.
19.
MEYERS, A. I., et al.. (1976). Detonation associated with oxidations of tetrahydropyranyl ether derivatives. A serious note of caution. Tetrahedron Letters. 17(28). 2417–2418. 6 indexed citations
20.
Olson, Gary L., et al.. (1976). A Stereospecific Synthesis of Vitamin A from 2,2,6‐Trimethyl‐cyclohexanone. Helvetica Chimica Acta. 59(2). 567–585. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shin‐ichi Tsukamoto Breakdown of academic impact, for papers by Elizabeth A. Lunney Breakdown of academic impact, for papers by John W. Ellingboe Breakdown of academic impact, for papers by Jefferson Tilley Breakdown of academic impact, for papers by John J. Piwinski Breakdown of academic impact, for papers by Steven E. Hall Breakdown of academic impact, for papers by John H. Hutchinson Breakdown of academic impact, for papers by William Seibel Breakdown of academic impact, for papers by Derek R. Buckle Breakdown of academic impact, for papers by Robert S. Wilhelm
Rankless by CCL
2026